+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders



Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders



Internal Medicine Journal 38(6): 422-426



The Janus kinase-2 (JAK-2) V617F mutation has been recently reported in patients with myeloproliferative disorders (MPD), which is believed to underlie growth factor hypersensitivity displayed by haematopoietic progenitors in these disorders. However, its frequency has been rarely determined in Taiwanese patients. The frequency of JAK2-V617F mutation in patients with polycythaemia vera, essential thrombocythaemia and idiopathic myelofibrosis (IMF) was determined in the DNA from the peripheral blood leucocytes of 108 patients by genomic polymerase chain reaction and restriction enzyme-based assay. The JAK2-V617F mutation could be detected in 28 of 33 polycythaemia vera patients (85%), 29 of 49 essential thrombocythaemia patients (59%) and 2 of 6 IMF patients (33%), but was not detected in 11 patients with myelodysplastic syndrome or another 10 with other haematological diseases. The presence of the JAK2 mutation was associated with specific MPD disease subtypes (P = 0.007), longer disease duration (P = 0.005), splenomegaly (P = 0.019), a higher white blood cell count (P = 0.002) and a higher haemoglobin level (P = 0.036). However, the overall risk of thrombosis or bleeding was not affected by the presence of the JAK2 mutation (32 vs 17%; P = 0.22). The JAK2-V617F mutation can be frequently detected in the Taiwanese patients with MPD disorders and therefore should be incorporated into the initial evaluation of patients suspected of MPD.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055162668

Download citation: RISBibTeXText

PMID: 18336541

DOI: 10.1111/j.1445-5994.2007.01589.x


Related references

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian Journal of Medical Research 132: 423-427, 2010

Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients. International Journal of Clinical and Experimental Pathology 8(9): 11555-9, 2015

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Irish Journal of Medical Science 176(2): 105-109, 2007

A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders. La Clinica Terapeutica 163(2): 109-113, 2012

The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders. Haematologica 93(5): 787-788, 2008

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology 14(6): 323-330, 2009

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1): 375-379, 2007

Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. American Journal of Surgical Pathology 31(2): 233-239, 2007

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. Journal of Thrombosis and Haemostasis 5(4): 708-714, 2007

The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. British Journal of Haematology 136(5): 745-751, 2007

Diagnostic Assays for the Jak2 V617F Mutation in Chronic Myeloproliferative Disorders. American Journal of Clinical Pathology 125(5): 651-653, 2006

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders. Journal of the Chinese Medical Association 70(3): 89-93, 2007

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106(6): 2162-2168, 2005

Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders. American Journal of Clinical Pathology 125(5): 651-653, 2006

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis. Turkish Journal of Gastroenterology 26(1): 42-48, 2015